©2020 Glysantis

Board of Directors

Randal Chase, PhD

Chairman of the Board

  • Grey LinkedIn Icon

Randal is a veteran biopharma executive, having led large companies such as Glaxo and Shire as well as startups like Medicago. Randal has raised >$500 million in biopharma investment. Randal has a PhD in biochemistry from UBC.

Tomas Mustelin, MD PhD

Independent Board Member

  • Grey LinkedIn Icon

Tomas is a leading clinician-scientist with extensive experience. Tomas has worked at Amgen, Gilead and MedImmune in leadership roles and has guided a number of new drugs through the drug development process. Tomas received his MD and PhD from the University of Helsinki. 

Phil Whiting, PhD

CEO, Glysantis

  • Grey LinkedIn Icon

Phil is a seasoned executive with years of experience leading businesses commercializing new technology, from clean tech to robotics, at large companies and startups. Phil has a PhD in chemistry from McGill University.